Ribomic Inc.

TSE:4591 Stock Report

Market Cap: JP¥4.5b

Ribomic Past Earnings Performance

Past criteria checks 0/6

Ribomic has been growing earnings at an average annual rate of 11.1%, while the Biotechs industry saw earnings declining at 12.5% annually. Revenues have been declining at an average rate of 56.5% per year.

Key information

11.08%

Earnings growth rate

22.97%

EPS growth rate

Biotechs Industry Growth31.91%
Revenue growth rate-56.47%
Return on equity-43.34%
Net Margin-15,852.13%
Next Earnings Update12 Nov 2026

Recent past performance updates

Recent updates

Analysis Article • Jun 09

We're Hopeful That Ribomic (TSE:4591) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 08

We're Hopeful That Ribomic (TSE:4591) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 18

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 12

We're Hopeful That Ribomic (TSE:4591) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 30

Companies Like Ribomic (TSE:4591) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 02

We're Not Very Worried About Ribomic's (TSE:4591) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Revenue & Expenses Breakdown

How Ribomic makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4591 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 268-1,189410839
31 Mar 263-1,145353803
31 Dec 251-1,042399665
30 Sep 250-1,053396346
30 Jun 251-991393640
31 Mar 252-1,018385667
31 Dec 242-962368696
30 Sep 242-949363686
30 Jun 241-944349687
31 Mar 240-1,024352764
31 Dec 2362-979350816
30 Sep 2362-1,3293771,126
30 Jun 2363-1,3743671,189
31 Mar 2365-1,6533611,491
31 Dec 2276-2,0463311,846
30 Sep 2278-1,7953241,618
30 Jun 2280-1,9613241,767
31 Mar 2280-1,6843131,482
31 Dec 2193-1,4482821,268
30 Sep 2192-1,3662701,207
30 Jun 2191-1,2552861,049
31 Mar 2191-1,187304957
31 Dec 20121-1,056337839
30 Sep 20122-1,044332823
30 Jun 20122-903325710
31 Mar 20121-855319673
31 Dec 1912-804342580
30 Sep 1910-761332543
30 Jun 198-779327562
31 Mar 197-836322612
31 Dec 1814-919324748
30 Sep 1830-904315759
30 Jun 1847-867307746
31 Mar 1864-753300663
31 Dec 1768-714285604
30 Sep 1777-700283621
30 Jun 1786-661282599
31 Mar 1793-646268610
31 Dec 16101-459254521
30 Sep 16103-393241453
30 Jun 16106-371225455
31 Mar 16121-323219435
31 Dec 15149-365217334
30 Sep 15173-317213313

Quality Earnings: 4591 is currently unprofitable.

Growing Profit Margin: 4591 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4591 is unprofitable, but has reduced losses over the past 5 years at a rate of 11.1% per year.

Accelerating Growth: Unable to compare 4591's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 4591 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.6%).

Return on Equity

High ROE: 4591 has a negative Return on Equity (-43.34%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/19 22:14
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ribomic Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kazuaki HashiguchiDaiwa Securities Co. Ltd.
Kiyokazu YamazakiIchiyoshi Research Institute Inc.